Zoetis Inc. $ZTS Shares Sold by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 27.1% during the first quarter, Holdings Channel.com reports. The firm owned 51,935 shares of the company’s stock after selling 19,351 shares during the period. Banque Cantonale Vaudoise’s holdings in Zoetis were worth $6,139,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis in the 4th quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC acquired a new position in Zoetis during the fourth quarter worth $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the third quarter worth $31,000. Finally, Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at $32,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research reports. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Morgan Stanley reissued an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a research note on Friday, May 15th. Stifel Nicolaus reduced their target price on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Finally, Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and an average target price of $133.92.

Zoetis Stock Up 1.7%

ZTS opened at $78.14 on Thursday. Zoetis Inc. has a one year low of $72.38 and a one year high of $161.77. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a market capitalization of $32.76 billion, a P/E ratio of 12.96, a price-to-earnings-growth ratio of 1.20 and a beta of 0.75. The business’s 50-day simple moving average is $90.47 and its 200-day simple moving average is $111.48.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the company earned $1.48 EPS. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.7%. Zoetis’s dividend payout ratio is currently 35.16%.

Insiders Place Their Bets

In related news, Director Paul Bisaro bought 2,000 shares of the stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by company insiders.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms announced or promoted class action lawsuits against Zoetis, with claims covering investors who bought shares between January 14, 2025 and May 6, 2026 and a lead-plaintiff deadline of July 27, 2026. The complaints allege investors were harmed by misleading disclosures about weakening veterinarian adoption and prescription trends. Article: Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
• Negative Sentiment: A shareholder securities fraud lawsuit has already been filed, adding legal overhang and potentially increasing costs, management distraction, and headline risk for the stock. Article: SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zoetis Inc. (ZTS)
• Neutral Sentiment: Zoetis was also mentioned in a broader healthcare momentum screen and brokerage commentary showing a “Hold” consensus, which suggests sentiment is cautious but not clearly improving. Article: 10 large and mega-cap U.S. healthcare stocks with the weakest momentum grades

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.